Teva is a is an Israel-based pharmaceutical company that develops and commercializes generic drugs for the treatment of cancer and respiratory diseases across the globe.
Business Model:
Revenue: $15.6B
Employees: 10,001-999,999
Address: Dvorah Haneviah 124
City: Tel Aviv
State: tel aviv district
Zip: 6329302
Country: IL
Teva is a is an Israel-based pharmaceutical company that develops and commercializes generic drugs for the treatment of cancer and respiratory diseases across the globe.
Contact Phone:
+19729267267
Contact Email:
Listed Exchange:
NYSE
IPO Date:
2/26/1982
Ticker Symbol:
TEVA
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2001 | Proneuron Biotechnologies | Venture Round | 0 |
7/2006 | TransPharma Medical | Series C | 0 |
9/2011 | Cocrystal Discovery | Venture Round | 0 |
3/2015 | Ignyta | Post-IPO Equity | 0 |
9/2006 | Gamida Cell | Series D | 0 |
9/2005 | BiolineRx | Venture Round | 0 |
5/2012 | Gamida Cell | Series E | 0 |
5/2017 | Heptares Therapeutics | Venture Round | 5M |
6/2015 | MicroCHIPS | Venture Round | 0 |
12/2015 | Wave Life Sciences | Equity | 30M |
5/2017 | Heptares Therapeutics | Venture Round | 0 |
12/2015 | Wave Life Sciences | Post-IPO Equity | 0 |
6/2015 | MicroCHIPS | Venture Round | 0 |
3/2015 | Ignyta | Post-IPO Equity | 0 |
5/2012 | Gamida Cell | Series E | 0 |
9/2011 | Cocrystal Discovery | Venture Round | 0 |
9/2006 | Gamida Cell | Series D | 0 |
7/2006 | TransPharma Medical | Series C | 0 |
9/2005 | BiolineRx | Venture Round | 0 |
12/2001 | Proneuron Biotechnologies | Venture Round | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2019 | Post-IPO Debt | $2.3B |
Bank of America Merrill Lynch & Co. HSBC Bank plc Barclays plc BNP Paribas Credit Suisse Morgan Stanley Mizuho Bank LTD. J.P. Morgan Chase Goldman Sachs MUFG Bank LTD Sumitomo Mitsui Banking Corporation PNC Bank National Association |
11/2019 | Post-IPO Debt | $2.1B | 11/2005 | Post-IPO Debt | $350M | 3/2018 | Post-IPO Debt | $4.5B | 12/2008 | Post-IPO Debt | $1.8B |
Bank Hapoalim B.M. Bank Leumi USA |
2/2018 | Post-IPO Equity | 1 | $358M |
Berkshire Hathaway Berkshire Hathaway Berkshire Hathaway Berkshire Hathaway |
---|
Announced Date | Name | Price |
---|---|---|
8/2016 | Anda | |
10/2015 | Representaciones e Investigaciones Médicas (Rimsa) | |
9/2015 | Gecko Health Innovations Inc. (formerly GeckoCap) | |
7/2015 | Actavis | |
3/2015 | Auspex Pharmaceuticals | |
6/2014 | Labrys Biologics | |
1/2014 | NuPathe | |
6/2013 | MicroDose Therapeutx | |
5/2011 | Cephalon | |
7/2008 | Barr Pharmaceuticals |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|